drugset / Trial / NCT02875587

Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome

NCT02875587

Phase 2 Completed 170 enrolled Aljazeera Hospital
RandomizedParallel-groupSingle-blindPrevention

Summary

The aim of this study is to compare the efficacy of calcium gluconate infusion versus cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who are at high risk for OHSS.

Timeline

Start
2016-10
Primary completion
2018-08
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cabergoline Small molecule 0.5 mg Oral
Subject calcium gluconate Small molecule 10 ml Intravenous